Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...

Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Prothena (PRTA – Research ...

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

In today's episode of Yeh Rishta Kya Kehlata Hai, Abhira and Armaan argue with Abhir and Kiara for making the wrong decision.

Insulet Corp. (PODD) on Thursday reported fourth-quarter profit of $100.7 million. On a per-share basis, the Acton, Massachusetts-based company said it had ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close.